This finding suggests that in CD47-MET fusion NSCLC, PD-L1 expression does not predict the efficacy of PD-1 inhibitors, which may be related to an immunosuppressive microenvironment. This evidence concerns the gene CD47 and non-small cell lung carcinoma.